22 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
29/04/2024 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
Buyback programs - March 2024 Monthly communication regarding buyback programs |
04/04/2024 | Description of buyback programs | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
Buyback programs – January 2024 Monthly communication regarding buyback programs |
02/02/2024 | Description of buyback programs | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is |
15/12/2010 | Public releases | |
November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as |
30/11/2010 | Public releases | |
Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing |
18/11/2010 | Public releases | |
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
19/10/2010 | Public releases |